72 related articles for article (PubMed ID: 29916918)
21. Advances in PET Imaging of the CXCR4 Receptor: [
Lindenberg L; Ahlman M; Lin F; Mena E; Choyke P
Semin Nucl Med; 2024 Jan; 54(1):163-170. PubMed ID: 37923671
[TBL] [Abstract][Full Text] [Related]
22. Additional Findings of 18 F-AIF-FAPI-42 PET/CT in a Patient With Mycosis Fungoides-Type Cutaneous T-Cell Lymphoma : Comparisons With 18 F-FDG PET/CT.
Liu G; Li Y; Du B; Cui Y; Li X
Clin Nucl Med; 2024 May; 49(5):e199-e201. PubMed ID: 38465934
[TBL] [Abstract][Full Text] [Related]
23. Increased Uptake of 68Ga-Pentixafor in Thymic Rebound After Chemotherapy in a Patient With Multiple Myeloma.
Pan Q; Luo Y; Cao X; Li J
Clin Nucl Med; 2021 Jan; 46(1):90-92. PubMed ID: 33181744
[TBL] [Abstract][Full Text] [Related]
24. Diagnostic efficacy of C-X-C motif chemokine receptor 4-directed PET/CT in newly diagnosed head and neck squamous cell carcinoma - a head-to-head comparison with [
Zhi Y; Werner RA; Schirbel A; Higuchi T; Buck AK; Kosmala A; Bley TA; Hagen R; Hackenberg S; Rosenwald A; Scherzad A; Gerhard-Hartmann E; Serfling SE
Am J Nucl Med Mol Imaging; 2023; 13(5):208-216. PubMed ID: 38023816
[TBL] [Abstract][Full Text] [Related]
25. Detecting CXCR4 Expression in Meningioma on
Krebs S; Schwartz J; Grommes C; Young RJ; Schöder H; Mayerhoefer ME
J Nucl Med; 2023 Apr; 64(4):667-668. PubMed ID: 36357178
[No Abstract] [Full Text] [Related]
26. 68Ga-Pentixafor PET/CT Improves the Detection of Recurrent Myeloma in the Temporal Bone Masked by the Physiological 18F-FDG Uptake of the Brain and Extraocular Muscles.
Pan Q; Luo Y; Cao X; Li J
Clin Nucl Med; 2022 Apr; 47(4):e348-e350. PubMed ID: 35020649
[TBL] [Abstract][Full Text] [Related]
27. Interobserver Agreement Rates on C-X-C Motif Chemokine Receptor 4-Directed Molecular Imaging and Therapy.
Hartrampf PE; Kosmala A; Serfling SE; Bundschuh L; Higuchi T; Lapa C; Rowe SP; Matsusaka Y; Weich A; Buck AK; Bundschuh RA; Werner RA
Clin Nucl Med; 2023 Jun; 48(6):483-488. PubMed ID: 36947793
[TBL] [Abstract][Full Text] [Related]
28. Automated Whole-Body Bone Lesion Detection for Multiple Myeloma on
Xu L; Tetteh G; Lipkova J; Zhao Y; Li H; Christ P; Piraud M; Buck A; Shi K; Menze BH
Contrast Media Mol Imaging; 2018; 2018():2391925. PubMed ID: 29531504
[TBL] [Abstract][Full Text] [Related]
29. Different extramedullary disease shown in chemokine receptor 4 targeted PET/CT with [68Ga]Ga-pentixafor in patients with Waldenström macroglobulinemia and smoldering disease.
Pan Q; Cao X; Li J; Li F; Luo Y
Nucl Med Commun; 2024 May; ():. PubMed ID: 38745523
[TBL] [Abstract][Full Text] [Related]
30. Considerations on PET/MR imaging of carotid plaque inflammation with
Toczek J; Riou L
J Nucl Cardiol; 2022 Apr; 29(2):503-505. PubMed ID: 32914318
[No Abstract] [Full Text] [Related]
31. MALT Lymphoma in Histologic Transformation: FDG-Avid but Pentixafor-Negative.
Tang R; Chen X; Liu M; Shu Q; Cai L
Clin Nucl Med; 2024 Mar; 49(3):276-277. PubMed ID: 38306380
[TBL] [Abstract][Full Text] [Related]
32. Cortisol-Producing Adrenal Adenomas With Intense Activity on 68Ga-Pentixafor PET/CT.
Ding J; Tong A; Zhang Y; Zhang H; Huo L
Clin Nucl Med; 2021 Apr; 46(4):350-352. PubMed ID: 33492858
[TBL] [Abstract][Full Text] [Related]
33. Imaging findings and clinical relevance of
Wang M; Zhang J; Ma J; Liu L; Wang J; Zhang C
BMC Med Imaging; 2023 Oct; 23(1):166. PubMed ID: 37884885
[TBL] [Abstract][Full Text] [Related]
34. Response assessment with the CXCR4-directed positron emission tomography tracer [
Herhaus P; Habringer S; Vag T; Steiger K; Slotta-Huspenina J; Gerngroß C; Wiestler B; Wester HJ; Schwaiger M; Keller U
EJNMMI Res; 2017 Dec; 7(1):51. PubMed ID: 28577295
[TBL] [Abstract][Full Text] [Related]
35. Upregulated myocardial CXCR4-expression after myocardial infarction assessed by simultaneous GA-68 pentixafor PET/MRI.
Rischpler C; Nekolla SG; Kossmann H; Dirschinger RJ; Schottelius M; Hyafil F; Wester HJ; Laugwitz KL; Schwaiger M
J Nucl Cardiol; 2016 Feb; 23(1):131-3. PubMed ID: 26667813
[No Abstract] [Full Text] [Related]
36. Erythrodermic mycosis fungoides: A case report.
Xu WB; Zhang YP; Zhou SP; Bai HY
World J Clin Cases; 2024 Jan; 12(1):130-135. PubMed ID: 38292631
[TBL] [Abstract][Full Text] [Related]
37. The Promise of Nuclear Imaging as an Alternative to Adrenal Venous Sampling for the Detection of Aldosterone-producing Adenomas.
Vaidya A
J Clin Endocrinol Metab; 2024 Mar; 109(4):e1363-e1364. PubMed ID: 37697945
[No Abstract] [Full Text] [Related]
38. Interesting Presentation of Mycosis Fungoides in Staging on F-18 FDG PET/CT.
Datta D; Sarwal T; Kumar R; Bairwa S; Gowda VN; Nalwa A
Nucl Med Mol Imaging; 2023 Oct; 57(5):243-246. PubMed ID: 37720879
[TBL] [Abstract][Full Text] [Related]
39. The Clinical Role of CXCR4-Targeted PET on Lymphoproliferative Disorders: A Systematic Review.
Zamanian M; Albano D; Treglia G; Rizzo A; Abedi I
J Clin Med; 2024 May; 13(10):. PubMed ID: 38792485
[No Abstract] [Full Text] [Related]
40. CXCR4-targeted Theranostics in Hematooncology: Opportunities and Challenges.
Werner R; Haug A; Buske C; Heidegger S; Illert AL; Bassermann F; Herhaus P; Buck A; Duell J; Topp MS; Kraus S; Einsele H; Lapa C; Raderer M; Lenz G; Habringer S; von Tresckow B; Keller U
Nuklearmedizin; 2024 Apr; 63(2):57-61. PubMed ID: 38190998
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
